News stories about Eiger Biopharmaceuticals (NASDAQ:EIGR) have been trending somewhat positive on Sunday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.9183280364726 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
EIGR stock traded down $1.20 during trading hours on Friday, hitting $9.10. The company’s stock had a trading volume of 64,458 shares, compared to its average volume of 68,335. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $95.80, a price-to-earnings ratio of -1.87 and a beta of 1.58. Eiger Biopharmaceuticals has a 12 month low of $6.10 and a 12 month high of $16.20.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.02) by ($0.09). research analysts expect that Eiger Biopharmaceuticals will post -4.22 EPS for the current fiscal year.
In other Eiger Biopharmaceuticals news, insider Joanne Quan sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $10.00, for a total value of $40,000.00. Following the completion of the sale, the insider now directly owns 4,000 shares of the company’s stock, valued at $40,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.80% of the company’s stock.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.